Notch2/3, are transmembrane receptors that, when activated, promote tumor growth, metastasis, and therapy resistance. Tarextumab's blockade aimed to suppress cancer stem cell populations and tumor progression. However, trials failed to demonstrate significant survival benefits, highlighting challenges in targeting Notch signaling in heterogeneous tumors.